Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HW211026
- Development stage
- Phase 2
- Lead developer
- Humanwell Healthcare
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
HW211026 is a chemical drug under development as a topical ointment, primarily for the treatment of actinic keratosis. It is being developed by Wuhan Humanwell Innovative Drug R & D Center. The drug is currently in Phase 1 clinical trials, with studies focused on evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers after single-dose administration. The mechanism of action and molecular target have not been disclosed publicly. Its primary therapeutic areas are neoplasms and skin/musculoskeletal diseases[1][2][3][4].
Beyond the preview
Go deeper on HW211026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HW211026.